Seroba Life Sciences

News, insights, analysis and data

← Back to Seroba Life Sciences profile

Seroba Life Sciences related stories

All articles and analysis

  • Prexton Therapeutics raises $31 mln
    Luisa Beltran- 7 February 2017

    Prexton Therapeutics said Feb. 7 that it has closed a 29 million euro ($31 million) Series B round led by Forbion Capital Partners and Seroba Life Sciences. Also participating were Merck Ventures (NL), Ysios Capital (ES) and Sunstone Capital (DK). Prexton, of Naarden, the Netherlands, is a biopharmaceutical company developing therapeutic compounds for the treatment of central nervous system conditions.

  • Irish biotech firm Heart Metabolics snags $20 mln Series A funds
    Iris Dorbian- 17 April 2014

    Heart Metabolics said Thursday that it has closed $20 million in Series A funding. The investors were venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. Based in Dublin, Ireland, Heart Metabolics is a biotech firm focused on developing treatments for cardio-metabolic diseases.

  • Gimv leads Series B round for Covagen
    Iris Dorbian- 10 December 2013

    Swiss biopharmaceutical company Covagen has raised has CHF 42 million in Series B financing. New investor Swiss biopharmaceutical company Covagen has raised CHF 42 million in Series B financing. New investor Gimv led the round with participation from Ascent Biomedical Ventures, Novartis Venture Fund, Edmond de Rothschild Investment Partners, Seroba Kernel Life Sciences, Ventech and MP Healthcare Venture Management. Also, Covagen has named Gimv's Dr. Karl Naegler and Ascent Biomedical Ventures' Dr. Avi Kometz to its board of directors.

  • Kernel Capital reaps benefits of Ireland's commitment to VC
    Staff Writer- 1 December 2013

    Commitments from state investor Enterprise Ireland helps Kernel Capital with latest fund

  • Ireland sets up public/private venture capital strategy for biotech sector
    PEI Staff- 29 December 2012

    The Irish government has launched a national strategy to develop its life sciences industry.

  • Funding European venture capital
    Brad Meikle- 1 June 2009

    The life of a VC on the fund raising trail has often been a tortuous one, never more so than in the midst of a recession. There are still capital pools to be tapped, however, but more efforts needs to be directed at loosening those purse strings.

  • Opsona Therapeutics Raises €18 Million
    VCJ Staff- 18 February 2009

    Opsona Therapeutics, a Dublin, Ireland-based developer of therapeutic and preventative approaches to autoimmune and inflammatory diseases, has raised €18 million in Series B funding. Participants included Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

  • peHUB Wire: Wednesday, February 18, 2009
    Brad Meikle- 18 February 2009

    Random Ramblings

  • peHUB Wire: Wednesday, February 18, 2009
    Brad Meikle- 18 February 2009

    Random Ramblings

  • Venture capital wanted
    Brad Meikle- 1 July 2007

    In Ireland, a buoyant economy with a strong focus on technology means the outlook for Irish venture capital firms is positive. But there are continuing challenges in attracting domestic institutional investment and building big-enough funds to compete with international players.